CS
DICE

Credit Suisse’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Credit Suisse’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69,258
Closed -$3.22M – 3207
2023
Q2 		$3.22M Buy
69,258
+42,855
+162% +$1.48M ﹤0.01% 1622
2023
Q1 		$756K Buy
26,403
+8
+0% +$237 ﹤0.01% 2490
2022
Q4 		$824K Buy
26,395
+17,399
+193% +$567K ﹤0.01% 2472
2022
Q3 		$181K Buy
8,996
+139
+2% +$2.53K ﹤0.01% 3283
2022
Q2 		$138K Buy
+8,857
New +$152K ﹤0.01% 3453

Credit Suisse's DICE Position: Q3 2023 in Review

Credit Suisse sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 69,258 shares — an estimated $3.22M sold.

Credit Suisse first reported a position in DICE in Q2 2022 and held it in 5 quarters. The position peaked at $3.22M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Credit Suisse reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Credit Suisse sold 69,258 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.22M.
  • Credit Suisse first reported a position in DICE Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Credit Suisse's DICE Therapeutics, Inc. Common Stock position peaked at $3.22M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.